tbuckley/cabot-search huggingface dataset:
Occupational Distribution of Campylobacteriosis and Salmonellosis Cases — Maryland, Ohio, and Virginia, 2014
Authors: Chia-ping Su, Marie A. de Perio, Kathleen Fagan, Meghan L. Smith, Ellen Salehi, Seth Levine, Karen Gruszynski, Sara E. Luckhaupt
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

Campylobacter and Salmonella are leading causes of bacterial gastroenteritis in the United States and are estimated to cause >1 million episodes of domestically acquired illness annually (1). Campylobacter and Salmonella are primarily transmitted through contaminated food, but animal-to-human and human-to-human transmission can also occur (2,3). Although occupationally acquired infections have been reported, occupational risk factors have rarely been studied. In 2015, the Occupational Safety and Health Administration (OSHA) identified 63 suspected or confirmed cases of Campylobacter infection over 3.5 years at a poultry-processing plant (Kathleen Fagan, OSHA, personal communication, December 2015); most involved new workers handling chickens in the "live hang" area where bacterial contamination is likely to be the highest. These findings were similar to those of a previous study of Campylobacter infections among workers at another poultry-processing plant (4). The investigation led to discussions among OSHA, state health departments, and CDC's National Institute for Occupational Safety and Health (NIOSH); and a surveillance study was initiated to further explore the disease incidence in poultry-processing plant workers and identify any additional occupations at increased risk for common enteric infections. Deidentified reports of campylobacteriosis and salmonellosis among Maryland, Ohio, and Virginia residents aged ≥16 years were obtained and reviewed. Each employed patient was classified into one of 23 major occupational groups using the 2010 Standard Occupational Classification (SOC) system.* Risk ratios (RR) and 95% confidence intervals (CI) for associations between each occupational group and each disease were calculated to identify occupations potentially at increased risk, contrasting each group with all other occupations. In 2014, a total of 2,977 campylobacteriosis and 2,259 salmonellosis cases were reported. Among the 1,772 (60%) campylobacteriosis and 1,516 (67%) salmonellosis cases in patients for whom occupational information was available, 1,064 (60%) and 847 (56%), respectively, were employed. Persons in farming, fishing, and forestry as well as health care and technical occupations were at significantly increased risk for both campylobacteriosis and salmonellosis compared with all other occupations. Targeting education and prevention strategies could help reduce disease, and improving the systematic collection of occupational information in disease surveillance systems could provide a better understanding of the extent of occupationally acquired diseases.
Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes
Authors: Geoffrey D. Clarke, Carolina Solis-Herrera, Marjorie Molina-Wilkins, Sandra Martinez, Aurora Merovci, Eugenio Cersosimo, Robert J. Chilton, Patricia Iozzo, Amalia Gastaldelli, Muhammad Abdul-Ghani, Ralph A. DeFronzo
Journal: Diabetes Care (2017)

OBJECTIVE To examine the effect of pioglitazone on myocardial insulin sensitivity and left ventricular (LV) function in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS Twelve subjects with T2D and 12 with normal glucose tolerance received a euglycemic insulin clamp. Myocardial glucose uptake (MGU) and myocardial perfusion were measured with [18F]fluoro-2-deoxy-d-glucose and [15O]H2O positron emission tomography before and after 24 weeks of pioglitazone treatment. Myocardial function and transmitral early diastolic relation/atrial contraction (E/A) flow ratio were measured with magnetic resonance imaging. RESULTS Pioglitazone reduced HbA1c by 0.9%; decreased systolic and diastolic blood pressure by 7 ± 2 and 7 ± 2 mmHg, respectively (P &amp;lt; 0.05); and increased whole-body insulin-stimulated glucose uptake by 71% (3.4 ± 1.3 to 5.8 ± 2.1 mg/kg · min; P &amp;lt; 0.01) in subjects with T2D. Pioglitazone enhanced MGU by 75% (0.24 ± 0.14 to 0.42 ± 0.13 μmol/min · g; P &amp;lt; 0.01) and myocardial perfusion by 16% (0.95 ± 0.16 to 1.10 ± 0.25 mL/min · g; P &amp;lt; 0.05). Measures of diastolic function, E/A ratio (1.04 ± 0.3 to 1.25 ± 0.4) and peak LV filling rate (349 ± 107 to 433 ± 99 mL/min), both increased (P &amp;lt; 0.01). End-systolic volume, end-diastolic volume, peak LV ejection rate, and cardiac output trended to increase (P not significant), whereas the ejection fraction (61 ± 6 to 66 ± 7%) and stroke volume increased significantly (71 ± 20 to 80 ± 20 L/min; both P &amp;lt; 0.05). CONCLUSIONS Pioglitazone improves whole-body and myocardial insulin sensitivity, LV diastolic function, and systolic function in T2D. Improved myocardial insulin sensitivity and diastolic function are strongly correlated.
A novel variant form of epidermal growth factor receptor (EGFR) protein in human lung cancer cell lines
Authors: Masaharu Nomura, Hiromasa Yamamoto, Mitsuo Sato, Kuntal Majmudar, Hisayuki Shigematsu, Takao Takahashi, Harubumi Kato, Kiyoshi Mukai, Masashi Yanagisawa, John Minna, Adi Gazdar
Journal: Cancer Research (2007)

3763   EGFR protein is frequently over expressed in various cancers and mutations occur in a subset of non small cell lung cancers (NSCLC). Of interest, the EGFR/KRAS pathway has not been implicated in small cell lung cancers (SCLC). Several variant forms of EGFR (type I to V) exist in malignant cells. We found a novel truncated form of egfr protein in lung cancer cell lines. The estimated size of the truncated protein was approximately 112 kDa and matched the size of the band found by Western blotting. The frequency of the truncated protein was greater in small cell lung carcinoma SCLC lines (16/20, 80%) than in NSCLC) lines (3/20, 15%). Affected lung cancer cells expressed truncated band alone or both truncated and wild type EGFR forms. The truncated protein had a cytoplasmic rather than cell surface localization and was generated by a post transcriptional event. Immunoprecipitation and N-terminal Edman amino acid sequence of this truncated egfr protein showed the cleavage point to be located in the middle of exon 5. The phospholylation site (Tyr 1068) of the truncated protein was constitutively active and not influenced by ligand stimulation. We designed siRNAs targeted against either the extra or intra-cellular domains which resulted in EGFR expression knockdown and decrease of the downstream phosphorylated proteins BRAF and MAPK. Liquid and soft agar culture assays showed decreased tumor cell proliferation after RNA interference mediated EGFR knockdown. The truncated EGFR protein presents a novel therapeutic target, especially for SCLC.
The transcriptional program, functional heterogeneity, and clinical targeting of mast cells
Authors: Gökhan Cildir, Harshita Pant, Angel F. Lopez, Vinay Tergaonkar
Journal: The Journal of Experimental Medicine (2017)

Mast cells are unique tissue-resident immune cells that express an array of receptors that can be activated by several extracellular cues, including antigen–immunoglobulin E (IgE) complexes, bacteria, viruses, cytokines, hormones, peptides, and drugs. Mast cells constitute a small population in tissues, but their extraordinary ability to respond rapidly by releasing granule-stored and newly made mediators underpins their importance in health and disease. In this review, we document the biology of mast cells and introduce new concepts and opinions regarding their role in human diseases beyond IgE-mediated allergic responses and antiparasitic functions. We bring to light recent discoveries and developments in mast cell research, including regulation of mast cell functions, differentiation, survival, and novel mouse models. Finally, we highlight the current and future opportunities for therapeutic intervention of mast cell functions in inflammatory diseases.
機能的心臓再生のための血管新生を促進する成長因子に埋め込まれたナノファイバーマトリックスニッチ工学【Powered by NICT】
Authors: Lakshmanan Rajesh, Kumaraswamy Priyadharshini, Krishnan Uma Maheswari, Sethuraman Swaminathan
Journal: Biomaterials (2016)
A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T‐cell lymphomas
Authors: Philip S. Boonstra, Avery Polk, Noah Brown, Alexandra C. Hristov, Nathanael G. Bailey, Mark S. Kaminski, Tycel Phillips, Sumana Devata, Tera Mayer, Ryan A. Wilcox
Journal: American Journal of Hematology (2017)

The transcription factor GATA-3, highly expressed in many cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphomas (PTCL), confers resistance to chemotherapy in a cell-autonomous manner. As GATA-3 is transcriptionally regulated by NF-κB, we sought to determine the extent to which proteasomal inhibition impairs NF-κB activation and GATA-3 expression and cell viability in malignant T cells. Proteasome inhibition, NF-κB activity, GATA-3 expression, and cell viability were examined in patient-derived cell lines and primary T-cell lymphoma specimens ex vivo treated with the oral proteasome inhibitor ixazomib. Significant reductions in cell viability, NF-κB activation, and GATA-3 expression were observed preclinically in ixazomib-treated cells. Therefore, an investigator-initiated, single-center, phase II study with this agent in patients with relapsed/refractory CTCL/PTCL was conducted. Concordant with our preclinical observations, a significant reduction in NF-κB activation and GATA-3 expression was observed in an exceptional responder following one month of treatment with ixazomib. While ixazomib had limited activity in this small and heterogeneous cohort of patients, inhibition of the NF-κB/GATA-3 axis in a single exceptional responder suggests that ixazomib may have utility in appropriately selected patients or in combination with other agents.
アップコンバージョンナノ粒子を用いたin vivoでの分化制御と幹細胞の長期追跡のための小分子の近赤外光誘起放出【Powered by NICT】
Authors: Li Jinming, Lee Wayne Yuk-Wai, Wu Tianyi, Xu Jianbin, Zhang Kunyu, Hong Wong Dexter Siu, Li Rui, Li Gang, Bian Liming
Journal: Biomaterials (2016)
Annual Meeting of the American Association for Cancer Research, Inc.
Authors: Y. CreechUtsumi, J. Hugh
Journal: JNCI Journal of the National Cancer Institute (1971)

Annual Meeting of the American Association for Cancer Research, Inc. Get access Y. CreechUtsumi, Y. CreechUtsumi Secretary-Treasurer American Association for Cancer Research The Institute for Cancer Research Fox Chase, Philadelphia, Penna. 19111 Search for other works by this author on: Oxford Academic PubMed Google Scholar J. Hugh J. Hugh Secretary-Treasurer American Association for Cancer Research The Institute for Cancer Research Fox Chase, Philadelphia, Penna. 19111 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 46, Issue 2, February 1971, Page 445, https://doi.org/10.1093/jnci/46.2.445 Published: 01 February 1971
Prenatal Antidepressant Use and Autism Spectrum Disorder—Reply
Authors: Simone N. Vigod, Tara Gomes, Joel G. Ray
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Increased Risk of Smoking in Female Adolescents Who Had Childhood ADHD
Authors: Irene J. Elkins, Gretchen R.B. Saunders, Stephen M. Malone, Margaret A. Keyes, Diana R. Samek, Matt McGue, William G. Iacono
Journal: American Journal of Psychiatry (2017)

Objective: This study examined the effects of childhood attention deficit hyperactivity disorder (ADHD) symptoms, both inattention and hyperactivity-impulsivity, on the development of smoking in male and female adolescents. Method: Twin difference methods were used to control for shared genetic and environmental confounders in three population-based, same-sex twin samples (N=3,762; 64% monozygotic). One cohort oversampled female adolescents with ADHD beginning in childhood. Regressions of childhood inattentive and hyperactive-impulsive symptoms were conducted to predict smoking outcomes by age 17. ADHD effects were divided into those shared between twins in the pair and those nonshared, or different within pairs. Results: Adolescents who had more severe ADHD symptoms as children were more likely to initiate smoking and to start smoking younger. The association of ADHD symptoms with daily smoking, number of cigarettes per day, and nicotine dependence was greater in females than in males. Monozygotic female twins with greater attentional problems than their co-twins had greater nicotine involvement, consistent with possible causal influence. These effects remained when co-occurring externalizing behaviors and stimulant medication were considered. Hyperactivity-impulsivity, while also more strongly related to smoking for female adolescents, appeared primarily noncausal. Conclusions: Smoking initiation and escalation are affected differentially by ADHD subtype and gender. The association of inattention with smoking in female adolescents may be causal, whereas hyperactivity-impulsivity appears to act indirectly, through shared propensities for both ADHD and smoking.
Death associated protein 5 (DAP5/p97/NAT1) is upregulated during retinoic acid-induced cell differentiation and DAP5/p86 is associated with arsenic trioxide-induced apoptosis in promyelocytic leukemia cells: A possible mechanism of leukemia cell differentiation and apoptosis
Authors: Isabel Zorrilla-Calancha, Bulent Ozpolat, Ugur Akar, Gabriel Lopez-Berestein
Journal: Cancer Research (2006)

2637  All-trans Retinoic Acid (ATRA) is a potent inducer of cellular differentiation in neoplastic cells including acute promyelocytic leukemia (APL), a type of acute myeloid leukemia (AML). Arsenic Trioxide (ATO), however, induces both partial differentiation at low and apoptosis at higher doses. Currently, the molecular mechanisms involved in leukemic cell differentiation and apoptosis are not fully understood. We recently reported that ATRA-induced downregulation of translation initiation factors, including eIF2, eIF4AI, eIF4G, and upregulation of death associated protein 5 (DAP5/p97/NAT1), a novel inhibitor of translational initiation (Blood, 104 (5) 2004). Translation initiation is a highly regulated process in response to mitogenic stimulation and plays a critical role in cell growth and proliferation. We hypothesized that ATRA-induced cell differentiation involves suppression of translation initiation, a rate limiting step of protein synthesis. DAP5/p97 has been shown to suppress cap-dependent and independent translational pathways. We are studying expression and regulation of DAP5 and its role in leukemia cell differentiation. We have found that ATRA and arsenic trioxide (ATO) induced DAP5/p97 protein and mRNA expression detected by western bloting and RT-PCR, respectively, during differentiation of NB4 APL cells. However, ATRA was unable to induce expression of DAP5 protein in ATRA-resistant NB4.R1 cells. ATRA also induced DAP5 protein and mRNA expression in HL60 cells. ATO at apoptotic doses (> 1 uM), but not ATRA, induced 86kDa caspase-cleaved proapoptotic product of DAP5, DAP5/p86, in NB4 cells, suggesting ATO-induced apoptosis is associated with the DAP5/p86 expression. Currently we are trying to downregulate DAP5/p97 expression using small interfering RNA (siRNA) in NB4 cells to evaluate the role of DAP5 in differentiation and apoptosis ATRA and ATO-induced respectively in acute promyelocytic leukemia. Our data suggests that a posttransptional regulation of gene expression through DAP5/p97-mediated translation control may be involved in terminal differentiation of myeloid cells. ATRA and ATO-induced supression of translational initiation through upregulation of DAP5/p97 and ATO (at high doses)-induced DAP5/p86 expression suggest a possible mechanism of action of these agents in leukemic cell differentiation and apoptosis.
Sulfhydryl Groups in Normal and Tumorous Hepatic Tissue Extracts Before and After Addition of Salts
Authors: Jesse P. Greenstein
Journal: JNCI Journal of the National Cancer Institute (1942)

Sulfhydryl Groups in Normal and Tumorous Hepatic Tissue Extracts Before and After Addition of Salts Get access Jesse P. Greenstein Jesse P. Greenstein senior biochemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 3, Issue 1, August 1942, Pages 61–67, https://doi.org/10.1093/jnci/3.1.61 Published: 01 August 1942
Plasma B-type natriuretic peptide levels in systolic heart failure
Authors: Richard W Troughton, David L Prior, Jeremy J Pereira, Maureen Martin, Annette Fogarty, Annitta Morehead, Timothy G Yandle, A.Mark Richards, Randall C Starling, James B Young, James D Thomas, Allan L Klein
Journal: Journal of the American College of Cardiology (2004)
多周波A FMと分子モデリングを用いた野生型及びoim/oimコラーゲン繊維の剛性と超微細構造における準原線維両レベル差起因する鎖置換の研究【Powered by NICT】
Authors: Li Tao, Chang Shu-Wei, Rodriguez-Florez Naiara, J Buehler Markus, Shefelbine Sandra, Dao Ming, Zeng Kaiyang
Journal: Biomaterials (2016)
Neuronal Depolarization Drives Increased Dopamine Synaptic Vesicle Loading via VGLUT
Authors: Jenny I. Aguilar, Matthew Dunn, Susana Mingote, Caline S. Karam, Zachary J. Farino, Mark S. Sonders, Se Joon Choi, Anna Grygoruk, Yuchao Zhang, Carolina Cela, Ben Jiwon Choi, Jorge Flores, Robin J. Freyberg, Brian D. McCabe, Eugene V. Mosharov, David E. Krantz, Jonathan A. Javitch, David Sulzer, Dalibor Sames, Stephen Rayport, Zachary Freyberg
Journal: Neuron (2017)
たこつぼ型心筋障害の亜型と考えられた左室mid‐portion ballooningの一例
Authors: 山口浩司, 若槻哲三, 福田大和, 小柴邦彦, 河野智仁, 山田博胤, 添木武, 岩瀬俊, 藤村光則, 赤池雅史, 東博之
Journal: Circulation (2006)
In older adults with subclinical hypothyroidism, levothyroxine did not improve symptoms or tiredness
Authors: Reema Shah
Journal: Annals of Internal Medicine (2017)

ACP Journal Club15 August 2017In older adults with subclinical hypothyroidism, levothyroxine did not improve symptoms or tirednessReema Shah, MDReema Shah, MDMcMaster University, Hamilton, Ontario, Canada (R.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2017-167-4-014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationStott DJ, Rodondi N, Kearney PM, et al; TRUST Study Group. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med. 2017;376:2534-44. https://pubmed.ncbi.nlm.nih.gov/28402245Clinical Impact RatingsGIM/FP/GP: Endocrinology: References1 Rodondi N, den Elzen WP, Bauer DC, et al; Thyroid Studies Collaboration. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304:1365-74. [PMID: 20858880] Google Scholar2 Pasqualetti G, Pagano G, Rengo G, Ferrara N, Monzani F. Subclinical hypothyroidism and cognitive impairment: systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100:4240-8. [PMID: 26305618] Google Scholar3 Villar HC, Saconato H, Valente O, Atallah AN. Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database Syst Rev. 2007;(3):CD003419. [PMID: 17636722] Google Scholar4 Monzani F, Caraccio N, Kozàkowà M, et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2004;89:2099-106. [PMID: 15126526] Google Scholar Author, Article, and Disclosure InformationAffiliations: McMaster University, Hamilton, Ontario, Canada (R.S.)This article was published at Annals.org on 1 August 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe impact of subclinical hypothyroidism on long-term outcomes in older patients undergoing percutaneous coronary intervention 15 August 2017Volume 167, Issue 4Page: JC14KeywordsDrugsElderlyHypothyroidismSerious adverse eventsSurgeryThyroidThyroid hormonesThyroid-stimulating hormoneThyroxine ePublished: 15 August 2017 Issue Published: 15 August 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
A phase II study of copper-depletion using tetrathiomolybdate (TM) in patients (pts) with breast cancer (BC) at high risk for recurrence: Updated results.
Authors: Sheena Sahota, Naomi Kornhauser, Amy Willis, Maureen M. Ward, Tessa Cigler, Anne Moore, Eleni Andreopoulou, Veronica Fitzpatrick, Sarah E. Schneider, Alysia Wiener, Anna Rubinchik, Sharrell Lee, Maureen E. Lane, Vivek Mittal, Linda T. Vahdat
Journal: Journal of Clinical Oncology (2017)

2557 Background: The tumor microenvironment (TME) plays a critical role in the spread of tumors. Bone marrow derived VEGFR2 + endothelial progenitor cells (EPCs) and copper-dependent lysyl oxidase (LOX) are key in tumor progression. We hypothesized TM-associated copper depletion inhibits tumor metastases by reducing the number of EPCs and other copper dependent (CD) processes in the pre-metastatic niche. These results are an update with longer follow-up. Methods: Phase II study of BC pts at high risk for recurrence, defined as node+ triple negative (TNBC), stage 3 and 4 with no evidence of disease (NED) were enrolled on a trial of CD with TM. Ceruloplasmin (Cp) levels were maintained between 8-16 mg/dl for two years with an extension phase or until relapse. The primary endpoint was change in EPCs measured by flow cytometry before and during treatment. Secondary endpoints included tolerability, safety, PFS and LOXL-2 levels. Results: 75 pts received 2650 cycles of TM on primary and extension study. The median age is 51 years (range 29-66). Forty-five pts have stage 2/3 BC and 30 with stage 4 NED. TNBC pts were 48% and 40% of pts are stage 4 NED. Median Cp level decreased from 28 to 16 (p &lt; 0.0001) after one cycle. Copper depletion was most efficient in TNBC where Cp levels dropped from 23.5 to 13 after one cycle. TM was well tolerated with grade 3/4 toxicities including: reversible neutropenia (2.3%), febrile neutropenia (0.04%), fatigue (0.2%). Five-year analysis showed a decrease in EPC’s (p = 0.004) and LOXL-2 (p &lt; 0.001). At a median follow-up of 6.9 years, the EFS for 75 pts is 75.6%. PFS for 36 pts with TNBC is 79.2%. EFS for stage 2/3 TNBC is 90% and for stage IV TNBC is 66.7%. Conclusions: TM is safe, well tolerated and appears to affect multiple components of the TME creating an inhospitable environment for tumor progression especially in high risk patients such as TNBC. Randomized trials are warranted, especially in patients at high risk for relapse. Clinical trial information: UL1TR000457.